Insmed Incorporated (INSM)


+0.29 (+1.76%)
Symbol INSM
Price $16.75
Beta 1.567
Volume Avg. 1.32M
Market Cap 2.285B
Shares () -
52 Week Range 16.04-28.94
1y Target Est -
DCF Unlevered INSM DCF ->
DCF Levered INSM LDCF ->
ROE -867.19% Strong Sell
ROA -29.07% Sell
Operating Margin -
Debt / Equity 1783.36% Strong Buy
P/E -4.23 Strong Sell
P/B 23.43 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest INSM news

Mr. William H. Lewis J.D., M.B.A.
NASDAQ Global Select

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.